CNS Pharmaceuticals
CNSPCNS Pharmaceuticals, Inc. is a biotechnology company focused on the development of innovative therapies for serious neurological and oncological diseases.
Table of contents
Earnings
Next report
Aug 17, 2026 (in a month)Competitors
By market cap
Profile
CNS Pharmaceuticals, Inc. is a biotechnology company focused on the development of innovative therapies for serious neurological and oncological diseases. The company recently underwent a strategic pivot to transition from a singular focus on glioblastoma to a broader portfolio of high-value, disease-modifying assets in neurology and oncology. Its core value proposition lies in identifying and acquiring preclinical and clinical-stage assets with strong biological rationales and clear regulatory pathways to address significant unmet medical needs.
The company is currently in a transitional phase, pivoting its strategy to build a diversified pipeline while seeking to monetize legacy assets through out-licensing.
Questions, answered.
- What is CNS Pharmaceuticals's market cap?
- CNS Pharmaceuticals (CNSP) has a market capitalization of $6.9M and trades on NASDAQ.
- Who are CNS Pharmaceuticals's competitors?
- CNS Pharmaceuticals's key competitors include Roivant Sciences, Ligand Pharmaceuticals, Fortress Biotech, and others. These companies compete in similar markets and product categories.
- Who does CNS Pharmaceuticals partner with?
- CNS Pharmaceuticals's notable partners include Cortice Biosciences, Inc., Reata Pharmaceuticals, Houston Pharmaceuticals, Inc. (HPI), and others.
- Where is CNS Pharmaceuticals headquartered?
- CNS Pharmaceuticals is headquartered in United States of America and employs approximately 3 people. It has been publicly traded since 2019.